HispanicBusiness

TORONTO, ONTARIO -- (Marketwired) -- 05/01/13 -- Biologix Hair Inc. (OTCBB: BLGX) (OTCQB: BLGX) has appointed Dave G. Csumrik to its Board of Directors. Mr. Csumrik will serve as an independent, non-executive Director and assist Biologix in developing its Audit, Compensation and Nominating Committees.

David Csumrik is the founder, sole shareholder and Chairman and CEO of Longview Associates, a group of companies domiciled in Barbados and the British Virgin Islands that provides management, administrative, accounting and facilities services to international business companies, trusts and foundations domiciled in these jurisdictions and other Caribbean countries. Through other companies in the group, Longview Associates operates an active investment and lending business.

In addition, Csumrik is a Director of Biologix Hair Science Ltd., the wholly owned Barbados subsidiary of Biologix Hair Inc. that holds the IP rights to Biologix Revive. Csumrik is Managing Director and significant shareholder in Linnaeus Inc., a Barbados-based plant biotechnology business licensed under the International Business Companies Act. He is also Managing Director of several International Business Companies located in Barbados and the British Virgin Islands and a Director of two banks located in Barbados licensed under the International Financial Services Act.

From 1988 until his relocation to Barbados in 1997, Csumrik practiced law, primarily in the fields of corporate finance and technology. He served as Chief Financial Officer of CSI Development Corp. (previously Consumers Software Inc.) from 1984-97, a software development and marketing company. When the company was sold to Microsoft Corp. in 1991 it entered the field of plant biotechnology. Csumrik previously provided management services in the areas of corporate finance and intellectual property licensing, held investments in several technology start-up companies and was treasurer with a small Canadian publicly held consumer products company.

David Csumrik earned a Bachelor of Arts in Economics and Accounting from the University of Toronto and a Bachelor of Laws degree from the University of British Columbia. He resides in Christ Church, Barbados.

Ron Holland, Biologix Director and CEO, stated, "As we advance towards making application to obtain a NYSE Market listing for our securities, Dave's independent financial experience and expertise is a welcome addition to our company's board of directors."

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.